Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches

In this second study, we established syngeneic in vivo models named carcinogen-induced mouse-derived isografts (cMDIs). Carcinogen-induced tumors were obtained during short-term observation (3⁻9 months) of CBA/J mice treated with various administration routes with 3-methylcholanthrene (MCA...

Full description

Bibliographic Details
Main Authors: Janette Beshay, Peter Jantscheff, Thomas Lemarchand, Cynthia Obodozie, Christoph Schächtele, Holger Weber
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/2/242
id doaj-a23669c0cb9d47378710994ff6e491e0
record_format Article
spelling doaj-a23669c0cb9d47378710994ff6e491e02020-11-25T00:27:20ZengMDPI AGCancers2072-66942019-02-0111224210.3390/cancers11020242cancers11020242Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic ApproachesJanette Beshay0Peter Jantscheff1Thomas Lemarchand2Cynthia Obodozie3Christoph Schächtele4Holger Weber5In Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, GermanyIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, GermanyTPL Pathology Labs, Sasbacher Str. 10, 79111 Freiburg, GermanyIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, GermanyIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, GermanyIn Vivo Pharmacology, ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, GermanyIn this second study, we established syngeneic in vivo models named carcinogen-induced mouse-derived isografts (cMDIs). Carcinogen-induced tumors were obtained during short-term observation (3&#8315;9 months) of CBA/J mice treated with various administration routes with 3-methylcholanthrene (MCA) or <i>N</i>-methyl-<i>N</i>-nitrosourea (MNU) as carcinogens. During necropsy, primary tumors and suspicious tissues were assessed macroscopically and re-transplanted (in PDX-like manner) into sex-matched syngeneic animals. Outgrowing tumors were histologically characterized as either spinocellular carcinoma (1/8) or various differentiated sarcomas (7/8). Growth curves of four sarcomas showed striking heterogeneity. These cMDIs were further characterized by flow cytometry, RNA sequencing, or efficacy studies. A variable invasion of immune cells into the tumors, as well as varying expression of tyrosine kinase receptor, IFN-&#947; signature, or immune cell population marker genes could be observed. Immune checkpoint inhibitor treatment (anti-mPD-1, anti-mCTLA-4, or a combination thereof) showed different responses in the various cMDI models. In general, cMDI models are carcinogen-induced tumors of low passage number that were propagated as tissue pieces in mice without any tissue culturing. Therefore, the tumors contained conserved tumor characteristics and intratumoral immune cell populations. In contrast to the previously described spontaneous MDI, carcinogen induction resulted in a greater number of individual but histologically related tumors, which were preferentially sarcomas.https://www.mdpi.com/2072-6694/11/2/242mouse tumor modelsexperimental cancermouse-derived isografts (MDIs)carcinogen-induced tumorstherapyimmune checkpoint inhibitorsimmunocompetent animalssyngeneic
collection DOAJ
language English
format Article
sources DOAJ
author Janette Beshay
Peter Jantscheff
Thomas Lemarchand
Cynthia Obodozie
Christoph Schächtele
Holger Weber
spellingShingle Janette Beshay
Peter Jantscheff
Thomas Lemarchand
Cynthia Obodozie
Christoph Schächtele
Holger Weber
Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
Cancers
mouse tumor models
experimental cancer
mouse-derived isografts (MDIs)
carcinogen-induced tumors
therapy
immune checkpoint inhibitors
immunocompetent animals
syngeneic
author_facet Janette Beshay
Peter Jantscheff
Thomas Lemarchand
Cynthia Obodozie
Christoph Schächtele
Holger Weber
author_sort Janette Beshay
title Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
title_short Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
title_full Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
title_fullStr Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
title_full_unstemmed Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
title_sort mouse-derived isograft (mdi) in vivo tumor models ii. carcinogen-induced cmdi models: characterization and cancer therapeutic approaches
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-02-01
description In this second study, we established syngeneic in vivo models named carcinogen-induced mouse-derived isografts (cMDIs). Carcinogen-induced tumors were obtained during short-term observation (3&#8315;9 months) of CBA/J mice treated with various administration routes with 3-methylcholanthrene (MCA) or <i>N</i>-methyl-<i>N</i>-nitrosourea (MNU) as carcinogens. During necropsy, primary tumors and suspicious tissues were assessed macroscopically and re-transplanted (in PDX-like manner) into sex-matched syngeneic animals. Outgrowing tumors were histologically characterized as either spinocellular carcinoma (1/8) or various differentiated sarcomas (7/8). Growth curves of four sarcomas showed striking heterogeneity. These cMDIs were further characterized by flow cytometry, RNA sequencing, or efficacy studies. A variable invasion of immune cells into the tumors, as well as varying expression of tyrosine kinase receptor, IFN-&#947; signature, or immune cell population marker genes could be observed. Immune checkpoint inhibitor treatment (anti-mPD-1, anti-mCTLA-4, or a combination thereof) showed different responses in the various cMDI models. In general, cMDI models are carcinogen-induced tumors of low passage number that were propagated as tissue pieces in mice without any tissue culturing. Therefore, the tumors contained conserved tumor characteristics and intratumoral immune cell populations. In contrast to the previously described spontaneous MDI, carcinogen induction resulted in a greater number of individual but histologically related tumors, which were preferentially sarcomas.
topic mouse tumor models
experimental cancer
mouse-derived isografts (MDIs)
carcinogen-induced tumors
therapy
immune checkpoint inhibitors
immunocompetent animals
syngeneic
url https://www.mdpi.com/2072-6694/11/2/242
work_keys_str_mv AT janettebeshay mousederivedisograftmdiinvivotumormodelsiicarcinogeninducedcmdimodelscharacterizationandcancertherapeuticapproaches
AT peterjantscheff mousederivedisograftmdiinvivotumormodelsiicarcinogeninducedcmdimodelscharacterizationandcancertherapeuticapproaches
AT thomaslemarchand mousederivedisograftmdiinvivotumormodelsiicarcinogeninducedcmdimodelscharacterizationandcancertherapeuticapproaches
AT cynthiaobodozie mousederivedisograftmdiinvivotumormodelsiicarcinogeninducedcmdimodelscharacterizationandcancertherapeuticapproaches
AT christophschachtele mousederivedisograftmdiinvivotumormodelsiicarcinogeninducedcmdimodelscharacterizationandcancertherapeuticapproaches
AT holgerweber mousederivedisograftmdiinvivotumormodelsiicarcinogeninducedcmdimodelscharacterizationandcancertherapeuticapproaches
_version_ 1725340607402999808